Aurinia Pharmaceuticals Inc (AUPH) Volatility At 3.50%, Should You Add A Position?

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is -12.01% lower on its value in year-to-date trading and has touched a low of $6.94 and a high of $12.43 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AUPH stock was last observed hovering at around $7.78 in the last trading session, with the day’s gains setting it 0.13%.

Currently trading at $7.91, the stock is 0.28% and -6.92% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.07 million and changing 1.67% at the moment leaves the stock -14.00% off its SMA200. AUPH registered -12.01% loss for a year compared to 6-month loss of -16.38%. The firm has a 50-day simple moving average (SMA 50) of $5.61 and a 200-day simple moving average (SMA200) of -$12.21.

Invest Like Buffett: Travel Back in Time & Grab This High-Potential Stock Before It Explodes

Imagine buying Apple for $1, Amazon for $2, or Tesla for $3. Now, imagine the same opportunity with a hidden gem trading under $3 right now.

Our premium newsletter, powered by AI and expert analysis, uncovers these time-travel investment opportunities.

Invest like Buffett and profit from undervalued gems before the market catches on.

Limited-time offer: Get your first month for just $2.90 and start your journey to wealth creation.


The stock witnessed a -12.01% gain in the last 1 month and extending the period to 3 months gives it a -4.58%, and is 2.33% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.50% over the week and 4.75% over the month.

Aurinia Pharmaceuticals Inc (AUPH) has around 300 employees, a market worth around $1.14B and $158.85M in sales. Profit margin for the company is -48.59%. Distance from 52-week low is 13.98% and -36.36% from its 52-week high. The company has generated returns on investments over the last 12 months (-16.40%).

Aurinia Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at -$0.16 with sales reaching $44.45M over the same period.The EPS is expected to grow by 31.58% this year, but quarterly earnings will post 30.50% year-over-year. Quarterly sales are estimated to grow 56.30% in year-over-year returns.

263 institutions hold shares in Aurinia Pharmaceuticals Inc (AUPH), with institutional investors hold 38.86% of the company’s shares. The shares outstanding are 142.27M, and float is at 130.56M with Short Float at 12.55%. Institutions hold 36.06% of the Float.

The top institutional shareholder in the company is Blackrock Inc. with over 8.33 million shares valued at $80.66 million. The investor’s holdings represent 5.81% of the AUPH Shares outstanding. As of Jun 29, 2023, the second largest holder is Armistice Capital, LLC with 4.69 million shares valued at $45.42 million to account for 3.27% of the shares outstanding. The other top investors are NEA Management Company, LLC which holds 3.97 million shares representing 2.77% and valued at over $38.43 million, while State Street Corporation holds 1.84% of the shares totaling 2.63 million with a market value of $25.48 million.

Aurinia Pharmaceuticals Inc (AUPH) Insider Activity

A total of 2 insider transactions have happened at Aurinia Pharmaceuticals Inc (AUPH) in the last six months, with sales accounting for 2 and purchases happening 0 times. The most recent transaction is an insider sale by Jayne David R.W., the company’s Director. SEC filings show that Jayne David R.W. sold 8,733 shares of the company’s common stock on May 23 at a price of $11.26 per share for a total of $98334.0. Following the sale, the insider now owns 49310.0 shares.

Aurinia Pharmaceuticals Inc disclosed in a document filed with the SEC on May 23 that MacKay-Dunn R. Hector (Director) sold a total of 4,818 shares of the company’s common stock. The trade occurred on May 23 and was made at $11.26 per share for $54251.0. Following the transaction, the insider now directly holds 24225.0 shares of the AUPH stock.

Still, SEC filings show that on May 23, Leversage Jill (Director) disposed off 4,815 shares at an average price of $11.26 for $54217.0. The insider now directly holds 18,528 shares of Aurinia Pharmaceuticals Inc (AUPH).

Aurinia Pharmaceuticals Inc (AUPH): Who are the competitors?

One of the company’s main competitors (and peers) include Regeneron Pharmaceuticals Inc. (REGN) that is trading 24.92% up over the past 12 months.AEterna Zentaris Inc. (AEZS) lies in the list of competitors of the Aurinia Pharmaceuticals Inc and is -50.58% lower over the same period from AUPHPieris Pharmaceuticals Inc. (PIRS) is -90.24% down on the 1-year trading charts.